Sanofi li­cens­es a pre­clin­i­cal ge­net­ic dis­ease drug from an un­known biotech spun out of the NIH

In a new deal Tues­day morn­ing, Sanofi is jump­ing in­to the an­ti­body-RNA con­ju­gate (ARC) space and el­e­vat­ing a lit­tle-known pri­vate biotech in­to the spot­light. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER